The high comorbidity burden of the hepatitis C virus infected population in the United States.
about
Conceptual framework for outcomes research studies of hepatitis C: an analytical reviewDosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyPharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.Biopsychosocial factors associated with pain in veterans with the hepatitis C virus.Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected AdultsIs hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological responseNational estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States.Current and future disease progression of the chronic HCV population in the United States.Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across TaiwanHepatitis C virus infection is not an independent risk factor for obstructive lung disease.Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease.A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney DiseaseNeuroplastic Effects of Transcranial Direct Current Stimulation on Painful Symptoms Reduction in Chronic Hepatitis C: A Phase II Randomized, Double Blind, Sham Controlled Trial.Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatinPain and opioid use in chronic liver diseaseChronic pain among liver transplant candidates.Protease inhibitors for hepatitis C: economic implications.Utility of evaluating HCV in an uninsured population.Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.Hospitalizations in Immigrants and Nonimmigrants Diagnosed With Chronic Hepatitis C Infection in Québec.Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011.Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010.Baseline Comorbidities Enhance the Risk of Treatment-Induced Depression in HCV-Infected Men: A Pilot Study.Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile.Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study.Influence of healthcare-associated factors on the efficacy of hepatitis C therapy
P2860
Q26745582-1F50C85E-70A6-44BF-B51D-AFEC6D53CBD5Q28080752-C7AD0640-9657-4E40-9BA6-782BCF3BDBF3Q30614811-F1720176-8B0F-4F88-9F33-0CDE0FBF3DCDQ33411348-7F45A081-05DA-4752-995B-5763C22FCE0FQ33756904-E1EB0019-94EB-4AC0-A3DE-20E5642F0E6EQ33813894-2D0A73A9-E1C3-4CD3-AA91-5CDD7098945CQ34128534-55FB4388-3C28-48AA-B48E-6BFF13578A61Q34143327-2FA8A1E8-F855-462E-B2E6-161800CA5AB3Q34310417-452DC14F-8364-45D8-968D-447893A90370Q34354269-7704BA54-C7E1-402E-8A99-CED493862AEAQ34737843-C67FEFA9-00D4-42C7-8A8F-BFA52E45529FQ34980383-5C292AE3-1C23-4C46-87CA-98E65181F102Q34998846-4FABBF88-92D0-467A-B23C-DA75CB476F42Q36006326-02DCE217-BA0A-44B3-B9D3-0F3FB97D7C26Q36195230-59503673-D40F-42D3-AB68-E2EC7CEABA5AQ36448117-0D4BCEC0-EF69-476D-8E57-A70850365EAAQ37026626-D7299B2F-DFA6-4038-A987-8CFECF650A0BQ37117154-B45E89C2-8852-4A37-8A28-DB5A3CC3456CQ38063055-DC7385F4-35F2-43C4-ADE9-AAF4E22A84F2Q38120496-113BF17B-564C-4F98-9589-07A414642F94Q38265121-BF5DF555-1D77-4C95-8124-2E556BE2F5A5Q38824198-5D26FF0F-D6CD-46EE-A206-353B9A1A2A23Q39911124-1E7957D7-FE87-4F33-9993-B8B4B79694BDQ40584139-D27894FC-C83B-4805-8A4B-3AD7EF831FAEQ41039250-3BA1F9B9-AAAD-4D87-B5DE-043112289F5CQ42237381-55A8CE29-6ED1-44F5-91A2-F5161D4750FAQ42239297-684BA39E-0A99-44DD-B444-A855312757E3Q45325371-F658A069-4E64-4066-9CED-06EEF20196C6Q47605707-4BDEEF32-85E3-479D-AC30-81B8F923117DQ51332911-D9A8EA6D-9AA6-437E-8951-D7213C88BC8BQ55093102-097EF443-452B-4064-A70A-937999AA56DFQ55339576-4B429434-78E4-47E8-8776-30256EF41ADCQ56917730-4C1176AD-1A27-4CB6-9463-A5C639C28C3A
P2860
The high comorbidity burden of the hepatitis C virus infected population in the United States.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The high comorbidity burden of ...... pulation in the United States.
@ast
The high comorbidity burden of ...... pulation in the United States.
@en
type
label
The high comorbidity burden of ...... pulation in the United States.
@ast
The high comorbidity burden of ...... pulation in the United States.
@en
prefLabel
The high comorbidity burden of ...... pulation in the United States.
@ast
The high comorbidity burden of ...... pulation in the United States.
@en
P2093
P2860
P356
P1476
The high comorbidity burden of ...... pulation in the United States.
@en
P2093
Jeanne M Pimenta
Karly S Louie
Linda M Mundy
Samantha St Laurent
Ulla M Forssen
P2860
P2888
P356
10.1186/1471-2334-12-86
P577
2012-04-11T00:00:00Z
P5875
P6179
1043458281